Results 81 to 90 of about 4,697 (156)

Supplemental figures from Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells

, 2017
Figure 1. Structures of acalabrutinib and ibrutinib. A. Chemical structure of acalabrutinib. B. Chemical structure of ibrutinib.
Mary Ayres (356964), William G. Wierda (12115368), Viralkumar Patel (15007709), Kumudha Balakrishnan (1322475), Michael J. Keating (7585280), Varsha Gandhi (147452), Elena Bibikova (71101)   +6 more
core   +1 more source

Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs

Journal of Comparative Effectiveness Research
Aim: Bruton’s tyrosine kinase inhibitors (BTKis), including ibrutinib and acalabrutinib, transformed the treatment landscape of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) by improving outcomes compared with ...
Lindsey Fitzgerald, Sabyasachi Ghosh, Alex Bokun, Angela Lax, Fan Mu, Eric Wu, Yilu Lin, Lizheng Shi, Zaina P Qureshi, Solomon A Graf   +9 more
doaj   +1 more source

Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.

Acalabrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia. We present results from ELEVATE-TN after a median follow-up of 74.5 months. Overall, 535 patients were randomized (acalabrutinib-obinutuzumab,
Munir, Talha, Kamdar, Manali, Flinn, Ian W., Banerji, Versha, Byrd, John C, Suterwala, Batul T., Hughes, Marie, Munugalavadla, Veerendra, Wun, Chuan-Chuan, Herishanu, Yair, Woyach, Jennifer A., Jurczak, Wojciech, Patel, Krish, Fogliatto, Laura Maria, Woyach, Jennifer A, Ferrant, Emmanuelle, Janssens, Ann, Sharman, Jeff P., Flinn, Ian W, Walker, Patricia, Ferrajoli, Alessandra, Skarbnik, Alan, Follows, George, Miranda, Paulo, Wierda, William G, Sharman, Jeff P, Walewska, Renata, Suterwala, Batul T, Byrd, John C., Wierda, William G., Egyed, Miklos, Ghia, Paolo, Wachira, Catherine Wangui   +32 more
core   +1 more source

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

, 2020
Introduction: Regimens involving intensive immuno-chemotherapy, followed by high-dose therapy and autologous stem cell transplant represent the standard treatment for younger fit patients with mantle cell lymphoma (MCL).
Galimberti S., Al-Janazreh H., Martino M., Morabito F., Cutrona G., Recchia A. G., Abu-Rayyan M., Vigna E., Atrash M., Botta C., Skafi M., Gentile M., Morabito L.   +12 more
core   +1 more source

A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas

Oncology and Therapy
Introduction Bruton tyrosine kinase inhibitor (BTKi) monotherapies have improved patient outcomes in B cell lymphomas; however, evidence on their comparative efficacy remains limited.
Pier Luigi Zinzani, Rhys Williams, Mei Xue, Binod Neupane, Priccila Zuchinali, Kyle Fahrbach, Heather Burnett, Dennis Sadic, Leyla Mohseninejad, Keri Yang   +9 more
doaj   +1 more source

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma [PDF]

, 2019
Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity ...
Morschhauser, F. (Franck), Le-Gouill, S. (Steven), Morschhauser, F. (Frank), Frigault, M.M. (Melanie M.), Doorduijn, J.K. (Jeanette), Smith, S.D. (Stephen D.), Lamy, T. (Thierry), Kate, A.P. (Arnon P.), Panizo, C. (Carlos), Yin, M. (Ming), Dupuis, J. (Jehan), Damaj, G. (Gandhi), Shah, B. (Bijal), Oberic, L. (Lucie), Casasnovas, O. (O.), Doorduijn, J.K. (Jeanette K.), Rule, S. (Simon), Robak, T. (Tadeusz), Casasnovas, R. O. (René Olivier), Davies, A. (Andrew), Raquel, Wang, M. (Michael), Jain, P. (Preetesh), Jacobsen, E. (Eric), Izumi, R. (Raquel), Długosz-Danecka, M. (Monika), Patel, P (Priti), Goy, A. (Andre), Nguyen, D. (Dorothy), Dlugosz-Danecka, M. (Monika), Zinzani, P.L. (Pier Luigi), Patel, P. (Priti), Zinzani, P.L. (P. L.), Le Gouill, S. (Steven), Eek, R. (Richard), Kater, A.P. (Arnon)   +35 more
core   +1 more source

Cost impact of Bruton’s tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia

Journal of Comparative Effectiveness Research
Aim: To estimate cost savings associated with covalent Bruton’s tyrosine kinase inhibitor (cBTKi) choice in patients with treatment-naive (TN) and relapsed/refractory (RR) chronic lymphocytic leukemia (CLL) from a Medicare perspective.
Adam S Kittai, Dipen A Patel, Jason Shafrin, Nadine Zawadzki, Vikram S Shetty, Yazan K Barqawi, Joanna M Rhodes   +6 more
doaj   +1 more source

Ibrutinib and acalabrutinib use and risk of incident atrial fibrillation: a propensity-matched analysis

Experimental Hematology & Oncology
Ibrutinib and acalabrutinib are both associated with an increased risk of atrial fibrillation (AF); however, the comparative risk of AF between these 2 BTK inhibitors remains largely unknown.
Joachim Alexandre, Jonaz Font, Thibault Lenormand, Sylvain Chantepie, Hippolyte Bardet, Gandhi Damaj, Charles Dolladille, Damien Legallois, Angélique Da-Silva, Paul Milliez, Arnaud Bisson, Laurent Fauchier   +11 more
doaj   +1 more source

Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)—an analysis of an administrative health claims database

Cardio-Oncology
Background First generation Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib have been associated with cardiovascular toxicities. Newer generation BTKi (e.g.,acalabrutinib and zanabrutinib) have been associated with lower incidence of ...
Srilakshmi Vallabhaneni, Srinath Adusumalli, Jingyi Wu, Peter W. Groeneveld, James Gerson, Rupal P. O’Quinn   +5 more
doaj   +1 more source

Acalabrutinib in treatment of patients with chronic lymphocytic leukemia including those at high genetic risk

Acta Haematologica Polonica
Acalabrutinib belongs to a class of Bruton’s tyrosine kinase inhibitors (BTKis) which have become one of the most widely used drugs for the treatment of B-cell malignancies including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL ...
Anna Ewa Wolska-Washer, Tadeusz Robak
doaj   +1 more source